A Randomized, Double-Blind Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Single Subcutaneous Administration of Lipegfilgrastim (Doses up to 100 μg/kg) in Healthy Japanese and Caucasian Subjects
Phase of Trial: Phase I
Latest Information Update: 05 Jun 2015
At a glance
- Drugs Lipegfilgrastim (Primary)
- Indications Neutropenia
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Merckle
- 02 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Apr 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
- 23 Mar 2015 Planned End Date changed from 1 Mar 2015 to 1 May 2015 as reported by ClinicalTrials.gov.